Aligos Therapeutics
ALGS
59 hedge funds and large institutions have $36M invested in Aligos Therapeutics in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 9 increasing their positions, 20 reducing their positions, and 30 closing their positions.
0.71% more ownership
Funds ownership: 74.51% → 75.21% (+0.71%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
22% less funds holding
Funds holding: 76 → 59 (-17)
47% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 30
48% less capital inflows, than outflows
Capital inflows: $6.44M | Capital outflows: $12.3M
55% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.1M |
| 2 |
NM
Newtyn Management
New York
|
+$1.31M |
| 3 |
Renaissance Technologies
New York
|
+$735K |
| 4 |
Millennium Management
New York
|
+$631K |
| 5 |
New York Life Investment Management
New York
|
+$295K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$3.7M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.17M |
| 3 |
BlackRock
New York
|
-$1.46M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.01M |
| 5 |
State Street
Boston,
Massachusetts
|
-$467K |
ALGS Hedge Fund Activity: Q2 2022 in Review
59 of the 5,962 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q2 2022, worth a combined $36M — down 47% from $68.4M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of ALGS and 16 opened new positions — a net loss of 14 holders — while 20 trimmed existing stakes and 9 added.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $2.1M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $3.7M sold.
- 59 institutional investors held Aligos Therapeutics (ALGS) as of Q2 2022, down from 76 in Q1 2022.
- Funds reported $36M of Aligos Therapeutics stock for Q2 2022, down 47% quarter-over-quarter.
- 16 funds opened new Aligos Therapeutics positions in Q2 2022 and 30 closed out, a net change of -14 holders.
- The largest Aligos Therapeutics buyer in Q2 2022 was Tang Capital Management, an estimated $2.1M added.
- The largest Aligos Therapeutics seller in Q2 2022 was Janus Henderson Group, an estimated $3.7M sold.
Based on aggregated 13F filings for Q2 2022.